SEC Filings
10x Genomics Seats A Stanford Immunologist And Glaukos's Operating Chief, With A New Audit Chair
Ansuman Satpathy and Joseph Gilliam joined the board as Class III directors, and Gilliam now chairs the audit committee.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
Ansuman Satpathy and Joseph Gilliam joined the board as Class III directors, and Gilliam now chairs the audit committee.
Earnings
The kidney-drug maker posted a $52.3 million third-quarter net loss against a $25.7 million profit a year earlier.
SEC Filings
Buybacks fell to $19.9 million last quarter as the all-stock deal turned into a $123.00-per-share cash purchase.
SEC Filings
The Class II director told AbbVie's board on Wednesday she would resign effective Monday, saying no dispute with the company was involved.
Earnings
Third-quarter sales rose 12% to $3.44 billion, while net income fell to $653.6 million on costs tied to the Crinetics purchase.
Earnings
The drug, bought with Soleno for about $2.9 billion, posted $106.7 million in third-quarter sales as the FDA weighs regulatory action.
SEC Filings
The subsidiary's revolver amendment also trims interest margins by 25 basis points and pushes maturity out to as late as October 2030.
Earnings
The Tulsa pipeline operator kept its $8.3 billion to $8.5 billion adjusted EBITDA outlook and said new power projects are coming soon.
SEC Filings
Stokely gives up the interim Executive Chair title but stays board chair, and the extra fees for him and David Whalen end.
SEC Filings
Jazz booked a $413.4 million operating loss on $1.24 billion of revenue as it also spent $225.0 million on buybacks.
SEC Filings
The Permian producer also raised its 2026 oil output guidance to about 524,000 barrels a day and nudged up its capital budget.
Earnings
The publisher's web sessions fell as AI search spread, and it expects $15-$20 million in severance costs in the fourth quarter.